Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics


Apellis Pharmaceuticals, Inc. (APLS)

Today's Latest Price: $47.22 USD

0.24 (-0.51%)

Updated Nov 27 1:00pm

Add APLS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

APLS Stock Price Chart Interactive Chart >

Price chart for APLS

APLS Price/Volume Stats

Current price $47.22 52-week high $49.42
Prev. close $47.46 52-week low $16.85
Day low $45.97 Volume 204,829
Day high $48.55 Avg. volume 969,152
50-day MA $35.71 Dividend yield N/A
200-day MA $32.17 Market Cap 3.58B

Apellis Pharmaceuticals, Inc. (APLS) Company Bio


Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.


APLS Latest News Stream


Event/Time News Detail
Loading, please wait...

APLS Latest Social Stream


Loading social stream, please wait...

View Full APLS Social Stream

Latest APLS News From Around the Web

Below are the latest news stories about Apellis Pharmaceuticals Inc that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Global IgA Nephropathy Market To See Astonishing Growth By 2027|Merck KGaA, Reata Pharmaceuticals, Inc, AbbVie, Inc., Allergan., Apellis Pharmaceuticals, Amgen Inc

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the IgA Nephropathy Market which would mention How the Covid-19 is affecting the IgA Nephropathy Industry, Market Trends and Potential Opportunities

OpenPR | September 30, 2020

Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results

* New Drug Application (NDA) and Marketing Authorization Application (MAA) Submissions for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for the Second Half of 2020 * Phase 3 DERBY and OAKS Trials Evaluating Pegcetacoplan in Geographic Atrophy (GA) Fully Enrolled; Top-line Data Expected in the Third Quarter of 2021 * PRINCE Trial Evaluating Pegcetacoplan in Treatment-Naïve PNH Patients Fully Enrolled; Top-line Data Expected in the First Half of 2021 * Cash and Investments of $833 Million as of June 30, 2020WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.“This past ...

Yahoo | July 31, 2020

Did Hedge Funds Make The Right Call On Apellis Pharmaceuticals, Inc. (APLS) ?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 13, 2020

Apellis advances late-stage studies of pegcetacoplan in vision loss disorder

Apellis Pharmaceuticals (APLS) has completed enrollment in two Phase 3 clinical trials, DERBY and OAKS, evaluating Fast Track-tagged pegcetacoplan (APL-2) in patients with geographic atrophy ((GA)) secondary to age-related macular degeneration, an eye disorder that can lead to blindness.The primary endpoint of both studies is the reduction in GA lesion...

Seeking Alpha | July 7, 2020

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of equity awards to three new employees with a grant date of July 1, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The employees received options to purchase 43,400 shares of Apellis common stock. The options have an exercise price of $31.96, which is equal to the closing price of Apellis common stock on July 1, 2020, the grant date of the options.

Yahoo | July 7, 2020

Read More 'APLS' Stories Here

APLS Price Returns

1-mo 45.97%
3-mo 75.74%
6-mo 40.16%
1-year 71.46%
3-year 252.91%
5-year N/A
YTD 54.21%
2019 132.15%
2018 -39.22%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7449 seconds.